GLIMPSE-1 model achieves state-of-the-art performance in antibody humanization and optimization, enabling scalable, structure-free biologic design from native human immune sequences.
Dr. Sullivan, who has decades of experience as a senior executive in the biotechnology and pharmaceutical industry, will be responsible for corporate and business development initiatives, as well as corporate and product strategic planning.
Dr. Patel is a seasoned life sciences executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong drug development expertise, including a track record of successful U.S. and global pharmaceutical licensing deals.
"Infinimmune, a biotechnology company pioneering new methods for antibody drug discovery and development, today announced a partnership with Grid Therapeutics (“Grid”), a clinical stage biotechnology company that focuses on human-derived antibodies, to collaborate in identifying new antibody drug candidates for non-small cell lung cancer."
"Infinimmune combines a world-class team of technologists with a state-of-the-art platform for the discovery, characterization, and validation of truly human antibodies,” said Eddie Eltoukhy, Partner at Pear VC.
